Childhood central nervous system tumors at MAHAK's Pediatric Cancer Treatment and Research Center (MPCTRC), Tehran, Iran

被引:18
|
作者
Mehrvar, Azim [1 ,2 ]
Faranoush, Mohammad [1 ,3 ]
Asl, Amir Abbas Hedayati [1 ]
Tashvighi, Maryam [1 ,4 ]
Fazeli, Mohammad Ali [1 ]
Qaddoumi, Ibrahim [5 ]
Mehrvar, Narjes [1 ]
Sobuti, Behdad [1 ]
Jafarpour, Ali [1 ]
Ravan parsa, Reza [6 ]
Zangooei, Rokhsaneh [1 ]
Alebouyeh, Mardawig [1 ]
Vossough, Parvaneh [1 ]
机构
[1] MAHAKs Pediat Canc Treatment & Res Ctr, Tehran 1956943512, Iran
[2] Army Med Sci Univ, Tehran, Iran
[3] Iranian Blood Transfus Org, Tehran, Iran
[4] Islam Azad Med Sci Univ, Ghom Branch, Tehran, Iran
[5] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA
[6] Islam Azad Med Sci Univ, Tehran Branch, Tehran, Iran
关键词
Brain tumor; CNS tumors; Children; Iran; BRAIN-TUMORS;
D O I
10.1007/s00381-013-2256-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As central nervous system (CNS) tumors account for second most common childhood malignancies and the first cause of mortality in children with cancer, improving treatment modalities can lead to increase the health care of patients. In this study, we examined the prevalence of childhood brain tumors in patients who referred to MAHAK's Pediatric Cancer Treatment and Research Center (MPCTRC) for treatment. A retrospective review of all children less than 15 years old with a CNS histologically proven tumor, who presented to MPCTRC from April 2007 to April 2010, was performed. Data was analyzed by SPSS version 19 with Kolmogorov-Smirnov and Chi-square tests. There were 198 (124 boys) children eligible for the study. The majority of the tumors were infratentorial (n = 134), and the rest were supratentorial (n = 60) and spinal (n = 4) cases. The median age was 6.11 +/- 3.65 years old. Medulloblastoma (n = 66), low-grade glioma (n = 52), and high-grade glioma (n = 40) were the most common tumors. The mean duration of follow-up was 21 months. At the time of this analysis, there were 105 (53 %) children alive, 82 (41.4 %) deaths, and 11 (5.6 %) lost for follow-up. The survival rate was 51.68 +/- 5.22 %. In contrast of high rate of death in this study, other general characteristics can serve as benchmark for improving our care for children with brain tumors in Iran.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 50 条
  • [1] Childhood central nervous system tumors at MAHAK’s Pediatric Cancer Treatment and Research Center (MPCTRC), Tehran, Iran
    Azim Mehrvar
    Mohammad Faranoush
    Amir Abbas Hedayati Asl
    Maryam Tashvighi
    Mohammad Ali Fazeli
    Ibrahim Qaddoumi
    Narjes Mehrvar
    Behdad Sobuti
    Ali Jafarpour
    Reza Ravan parsa
    Rokhsaneh Zangooei
    Mardawig Alebouyeh
    Parvaneh Vossough
    [J]. Child's Nervous System, 2014, 30 : 491 - 496
  • [2] THE EPIDEMIOLOGY OF CHILDHOOD BRAIN TUMORS AT MAHAK PEDIATRIC CANCER TREATMENT AND RESEARCH CENTER (MPCTRC), TEHRAN, IRAN
    Faranoush, Mohammad
    Mehrvar, Azim
    Asl, Amir Abbas Hedayati
    Tashvighi, Maryam
    Parsa, Reza Ravan
    Fazeli, Mohammad Ali
    Sobuti, Behdad
    Mehrvar, Narjes
    Ali, Jafarpour
    Zangooei, Rokhsaneh
    Alebouyeh, Mardawij
    Vossough, Parvaneh
    [J]. NEURO-ONCOLOGY, 2012, 14 : 108 - 108
  • [3] FOLLOW-UP OF CHILDHOOD BRAIN TUMORS AT MAHAK PEDIATRIC CANCER TREATMENT AND RESEARCH CENTER (MPCTRC), TEHRAN, IRAN
    Mehrvar, A.
    Asl, A. A. Hedayati
    Faranoush, M.
    Tashvighi, M.
    Fazeli, M. A.
    Mehrvar, N.
    Zangooei, R.
    Alebouyeh, M.
    Vossough, P.
    [J]. PEDIATRIC BLOOD & CANCER, 2013, 60 : 141 - 141
  • [4] Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran
    Mehrvar, Azim
    Qaddoumi, Ibrahim
    Tashvighi, Maryam
    Naderi, Ali
    Mousakhani, Hadi
    Alasvand, Ramin
    Shekarchi, Babak
    Afsar, Negar
    Nourian, Mahyar
    Mehrvar, Narjes
    [J]. SEMINARS IN ONCOLOGY, 2021, 48 (4-6) : 295 - 303
  • [5] LEUKEMIA PREDISPOSITION: A REPORT OF CHILDHOOD ACUTE MYELOID LEUKEMIA AT MAHAK'S PEDIATRIC CANCER TREATMENT AND RESEARCH CENTER
    Mehrvar, A.
    Tashvighi, M.
    Faranoush, M.
    Reinhardt, D.
    Mofrad, N. Niktoreh
    Asl, A. A. Hedayati
    Alebouyeh, M.
    [J]. PEDIATRIC BLOOD & CANCER, 2015, 62 : S323 - S323
  • [6] Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020
    Mehrvar, Azim
    Mehrvar, Narjes
    Sadeghi, Yasaman
    Tashvighi, Maryam
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S272 - S277
  • [7] Outcome of Primary Childhood Central Nervous System Tumors: Results from a Single Center in Iran
    Rafsanjani, Kh. Arjmandi
    Bahoush, Gr.
    Nikpoor, F.
    Vossough, P.
    [J]. NEUROPEDIATRICS, 2012, 43 (05) : 232 - 237
  • [8] EVALUATION OF THE INCIDENCE OF CENTRAL NERVOUS SYSTEM TUMORS IN A CHILDHOOD CANCER TREATMENT CENTER AND THE CREATION OF A SPECIFIC GROUP
    Azambuja, Alessandra
    Barreto, Juliana
    Cristofani, Lilian Maria
    Sanders, Felipe
    Baraldi, Helena
    Weltman, Eduardo
    Lucato, Leandro
    Paes, Vitor
    Frassetto, Fernando
    Petitto, Carlo
    Rosemberg, Sergio
    Matushita, Hamilton
    Odone, Vicente
    [J]. NEURO-ONCOLOGY, 2020, 22 : 319 - 319
  • [9] Retrospective Evaluation of Childhood Central Nervous System Tumors Followed in a Pediatric Hematology Oncology Center: A Single Center Experience
    Genc, Asli
    Yazal Erdem, Arzu
    Emir, Suna
    Ozyoruk, Derya
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2024, 34 (01): : 45 - 51
  • [10] Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience
    Susam-Sen, Hilal
    Varan, Ali
    Bajin, Inci
    Gocmen, Rahsan
    Aydin, Burca
    Yalcin, Bilgehan
    Kurucu, Nilgun
    Kutluk, Tezer
    Bayhan, Turhan
    Akyuz, Canan
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (08) : 1769 - 1777